RACB
Research Alliance Corp. II [RACB] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RACB Stock Summary
In the News
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Research Alliance Corp. I - RACA
NEW YORK, March 27, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Research Alliance Corp. I ("RACA" or the "Company") (RACA) relating to its proposed merger with POINT Biopharma, Inc. Under the terms of the agreement, RACA will acquire POINT through a reverse merger, with POINT emerging as a publicly traded company. The investigation focuses on whether Research Alliance Corp. I and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, 2) whether the transaction is properly valued, and 3) whether all material information has been disclosed.
RACB Financial details
RACB Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2021-12-31 |
|---|---|---|
| Revenue per share | 0 | |
| Net income per share | -0.02 | |
| Operating cash flow per share | -0.03 | |
| Free cash flow per share | -0.03 | |
| Cash per share | 0.05 | |
| Book value per share | -0.22 | |
| Tangible book value per share | 7.58 | |
| Share holders equity per share | -0.22 | |
| Interest debt per share | 0 | |
| Market cap | 185.53M | |
| Enterprise value | 184.48M | |
| P/E ratio | -406.87 | |
| Price to sales ratio | 0 | |
| POCF ratio | -353.71 | |
| PFCF ratio | -353.71 | |
| P/B Ratio | -44.77 | |
| PTB ratio | -44.77 | |
| EV to sales | 0 | |
| Enterprise value over EBITDA | -394.5 | |
| EV to operating cash flow | -351.71 | |
| EV to free cash flow | -351.71 | |
| Earnings yield | 0 | |
| Free cash flow yield | 0 | |
| Debt to equity | 0 | |
| Debt to assets | 0.04 | |
| Net debt to EBITDA | 2.25 | |
| Current ratio | 7.04 | |
| Interest coverage | 0 | |
| Income quality | 1.15 | |
| Dividend Yield | 0 | |
| Payout ratio | 0 | |
| Sales general and administrative to revenue | 0 | |
| Research and developement to revenue | 0 | |
| Intangibles to total assets | 0 | |
| Capex to operating cash flow | 0 | |
| Capex to revenue | 0 | |
| Capex to depreciation | 0 | |
| Stock based compensation to revenue | 0 | |
| Graham number | 0.34 | |
| ROIC | 0 | |
| Return on tangible assets | 0 | |
| Graham Net | -0.23 | |
| Working capital | 1.08M | |
| Tangible asset value | 0 | |
| Net current asset value | -4.16M | |
| Invested capital | 0 | |
| Average receivables | 0 | |
| Average payables | 13.5K | |
| Average inventory | 0 | |
| Days sales outstanding | 0 | |
| Days payables outstanding | 0 | |
| Days of inventory on hand | 0 | |
| Receivables turnover | 0 | |
| Payables turnover | 0 | |
| Inventory turnover | 0 | |
| ROE | 0.11 | |
| Capex per share | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
| Metric | History | 2021-06-30 | 2021-09-30 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.03 | -0.03 | -0.07 | 0 | 0.11 | |
| Operating cash flow per share | -0.16 | 0 | -0.07 | -0.03 | -0.05 | |
| Free cash flow per share | -0.16 | 0 | -0.07 | -0.03 | -0.05 | |
| Cash per share | 0.28 | 0.27 | 0.18 | 0.15 | 0.09 | |
| Book value per share | 34.38 | 34.35 | 34.24 | 34.25 | 34.36 | |
| Tangible book value per share | 34.38 | 34.35 | 34.24 | 34.25 | 34.36 | |
| Share holders equity per share | 34.38 | 34.35 | 34.24 | 34.25 | 34.36 | |
| Interest debt per share | 0 | 0 | 0 | 0.04 | 0.16 | |
| Market cap | 42.96M | 41.73M | 41.35M | 41.52M | 41.64M | |
| Enterprise value | 41.76M | 40.58M | 40.59M | 40.9M | 41.24M | |
| P/E ratio | -81.24 | -72.28 | -35.51 | 570.58 | 21.39 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -62.84 | -2.85K | -142.11 | -294.82 | -192.41 | |
| PFCF ratio | -62.84 | -2.85K | -142.11 | -294.82 | -192.41 | |
| P/B Ratio | 0.29 | 0.29 | 0.29 | 0.29 | 0.29 | |
| PTB ratio | 0.29 | 0.29 | 0.29 | 0.29 | 0.29 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -307.26 | -274 | -133.32 | -238.18 | -238.07 | |
| EV to operating cash flow | -61.09 | -2.78K | -139.5 | -290.43 | -190.55 | |
| EV to free cash flow | -61.09 | -2.78K | -139.5 | -290.43 | -190.55 | |
| Earnings yield | 0 | 0 | -0.01 | 0 | 0.01 | |
| Free cash flow yield | -0.02 | 0 | -0.01 | 0 | -0.01 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | |
| Net debt to EBITDA | 8.8 | 7.75 | 2.5 | 3.6 | 2.32 | |
| Current ratio | 12.86 | 8.52 | 4.98 | 4.58 | 7.31 | |
| Interest coverage | 0 | 0 | -22.84 | -0.9 | -0.26 | |
| Income quality | 5.17 | 0.1 | 1 | -7.74 | -0.44 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 4.91 | 5.13 | 7.28 | 1.82 | 9.43 | |
| ROIC | 0 | 0 | 0 | 0 | 0 | |
| Return on tangible assets | 0 | 0 | 0 | 0 | 0 | |
| Graham Net | -0.98 | -1 | -1.1 | -1.13 | -1.16 | |
| Working capital | 1.26M | 1.23M | 772.59K | 600.88K | 427.64K | |
| Tangible asset value | 0 | 0 | 0 | 0 | 0 | |
| Net current asset value | -3.97M | -4M | -4.46M | -4.63M | -4.8M | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 51.82K | 55.65K | 90.31K | 55.45K | 33.32K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0 | 0 | 0 | 0 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
RACB Frequently Asked Questions
What is Research Alliance Corp. II stock symbol ?
Research Alliance Corp. II is a US stock , located in Las vegas of Nv and trading under the symbol RACB
Is Research Alliance Corp. II stock public?
Yes, Research Alliance Corp. II is a publicly traded company.
Company Profile
- Volume Average 205.78K
- Market Capitalization 193.88M
- CEO Dr. Peter Kolchinsky Ph.D.
- Headquarters Las Vegas,NV,US
- IPO Date 2021-03-18
-
Website
https://www.researchalliancecorpii.com 
Research Alliance Corp. II does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It identifies and acquires a business, focusing on the healthcare industry, such as in biotechnology sector. Research Alliance Corp. II was incorporated in 2020 and is based in Las Vegas, Nevada.
